Collaboration project agreement between MAB Discovery GmbH and BioNTech AG
- Category: More News
- Published on Monday, 06 November 2017 15:01
- Hits: 411
NEURIED, Germany I November 6, 2017 I MAB Discovery GmbH today announced that it has entered into the second collaboration project agreement with BioNTech AG, Mainz. The unique MAB Discovery technology platform for the generation of novel antibody therapeutics will be applied for proprietary targets provided by BioNTech. Financial terms of the agreement were not disclosed.
“We are excited to be selected again as a partner for BioNTech. This underscores the high performance of our rabbit-based antibody discovery platform,” said Dr. Stephan Fischer, CEO of MAB Discovery.
Sean Marett, COO of BioNTech added, “Our collaboration with MAB Discovery in 2013 was highly productive and we are delighted to expand our relationship to generate unique antibodies against a set of therapeutically relevant targets.”
MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization, and delivers a vast number of high quality candidates with regard to potency and epitope coverage. The use of wild type rabbits for immunization and the functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens, e.g. GPCRs, ion channels, carbohydrates, and small sized epitopes.
About MAB Discovery GmbH
MAB Discovery, based in Munich, was founded and established in 2010 by experienced pharma scientists with proven track record in drug development. MAB Discovery complies with the highest industrial standards of big pharma, but operates with the flexibility, speed and innovative spirit of young biotech’s. The company’s outstanding technology platform generally offers its collaboration partners access to a large variety of functional drug candidates to choose from, and a unique route to CMC-compliant humanized mAb’s in 10-12 months.
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
More information about BioNTech is available at www.biontech.de.
SOURCE: MAB Discovery